Pettyjohn Wood & White’s Vertex Pharmaceuticals VRTX Stock Holding History

Pettyjohn Wood & White’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-889	Closed	-$358K	–	199
2024 Q4	$358K	Hold	889	–	–	0.07%	151
2024 Q3	$413K	Hold	889	–	–	0.08%	140
2024 Q2	$417K	Buy	889 +50	+6%	+$21.7K	0.08%	135
2024 Q1	$351K	Sell	839 -28	-3%	-$11.8K	0.07%	148
2023 Q4	$353K	Hold	867	–	–	0.08%	145
2023 Q3	$301K	Hold	867	–	–	0.07%	149
2023 Q2	$305K	Sell	867 -23	-3%	-$7.75K	0.07%	147
2023 Q1	$280K	Hold	890	–	–	0.07%	146
2022 Q4	$257K	Hold	890	–	–	0.06%	150
2022 Q3	$258K	Hold	890	–	–	0.07%	147
2022 Q2	$251K	Buy	+890	New	+$238K	0.06%	152

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Pettyjohn Wood & White's VRTX Position: Q1 2025 in Review

Pettyjohn Wood & White sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 889 shares — an estimated $358K sold.

Pettyjohn Wood & White first reported a position in VRTX in Q2 2022 and held it in 11 quarters. The position peaked at $417K in Q2 2024. 1,617 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

Pettyjohn Wood & White reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Pettyjohn Wood & White sold 889 Vertex Pharmaceuticals shares in Q1 2025, an estimated $358K.
Pettyjohn Wood & White first reported a position in Vertex Pharmaceuticals in Q2 2022 and held it in 11 quarters.
Pettyjohn Wood & White's Vertex Pharmaceuticals position peaked at $417K in Q2 2024.
1,617 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Pettyjohn Wood & White's 13F filing for Q1 2025, filed 8 May 2025.